参考文献

[1]向阳，宋鸿钊.滋养细胞肿瘤学[M].3版.北京：人民卫生出版社，2011.

[2]Berkowitz R S,Goldstein D P.Gestational trophoblastic diesase//Berek J S.Berek & Novak’s Gynecology.15th ed.Philadelphia:Lippincott Williams & Wilkins,2012：1581-1603.

[3]Ngan H Y,Seckl M J,Berkowitz R S,et al.FIGO Cancer report 2015:Update on the diagnosis and management of gestational trophoblastic disease.Int J Gynecol Obstet,2015,13(Suppl 2):s123-s126.

[4]Kurman R J,Carcangiu M L,Herrington C S,et al,WHO Classification of Tumours of Female Reproductive Organs [M].4th edition,2014,www.who.int/bookorders.(https://www.daowen.com)

[5]Lawrie T A,Alazzam M,Tidy J,et al.First-line chemotherapy in low-risk gestational trophoblastic neoplasia.Cochrane Database Syst Rev ,2016(6):CD007102.

[6]Bolze P A,Riedl C,Massardier J,et al.Mortality rate of gestational trophoblastic neoplasia with a FIGO score of≥13 [J].American journal of obstetrics and gynecology,2016,214(3):390.e1-8.

[7]Yang J,Xiang Y,Wan X,et al.Primary treatment of stage IV gestational trophoblastic neoplasia with floxuridine,dactinomycin,etoposide and vincristine(FAEV):A report based on our 10-year clinical experiences [J].Gynecologic oncology,2016,143(1):68-72.

[8]Feng F,Xiang Y,Wan X,et al.Salvage combination chemotherapy with floxuridine,dactinomycin,etoposide,and vincristine(FAEV)for patients with relapsed/chemoresistant gestational trophoblastic neoplasia [J].Annals of oncology :official journal of the European Society for Medical Oncology / ESMO,2011,22(7):1588-1594.